Advanced search
Publication Cover
Leukemia & Lymphoma Volume 18, 1995 - Issue 5-6
Submit an article Journal homepage
940
Views
238
CrossRef citations to date
0
Altmetric
Original Article

CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy

R. H. Scheuermann Laboratory of Molecular Pathology and Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
&
E. Racila Department of Microbiology and Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Pages 385-397 | Received 06 Sep 1994, Published online: 01 Jul 2009

Citations (238)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (22)

Tian Huan, Bugao Guan, Hongbo Li, Xiu Tu, Chi Zhang & Bin Tang. (2023) Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer. Human Vaccines & Immunotherapeutics 19:2.
Read now
Jared A Cohen & Armin Ghobadi. (2022) Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. Expert Review of Anticancer Therapy 22:9, pages 903-914.
Read now
Huan Zhang, Man Liu, Qing Li, Cuicui Lyu, Yan-Yu Jiang, Juan-Xia Meng, Jing-Yi Li & Qi Deng. (2022) Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system. Leukemia & Lymphoma 63:2, pages 353-361.
Read now
Audrey M Sigmund, Kieran D Sahasrabudhe & Bhavana Bhatnagar. (2020) Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy 10, pages 7-20.
Read now
Matthew H Forsberg, Amritava Das, Krishanu Saha & Christian M Capitini. (2018) The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Therapeutics and Clinical Risk Management 14, pages 1573-1584.
Read now
Michael D Jain, Christina A Bachmeier, Vania H Phuoc & Julio C Chavez. (2018) Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma. Therapeutics and Clinical Risk Management 14, pages 1007-1017.
Read now
Antonia Rotolo, Anastasios Karadimitris & Marco Ruella. (2018) Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. Leukemia & Lymphoma 59:9, pages 2040-2055.
Read now
Thomas Shum, Robert L. Kruse & Cliona M. Rooney. (2018) Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opinion on Biological Therapy 18:6, pages 653-664.
Read now
Alessandro Crotta, Jie Zhang & Christopher Keir. (2018) Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Current Medical Research and Opinion 34:3, pages 435-440.
Read now
Elisa Landoni & Barbara Savoldo. (2018) Treating hematological malignancies with cell therapy: where are we now?. Expert Opinion on Biological Therapy 18:1, pages 65-75.
Read now
Meng Li, Zeng-Shan Liu, Xi-Lin Liu, Qi Hui, Shi-Ying Lu, Lin-Lin Qu, Yan-Song Li, Yu Zhou, Hong-Lin Ren & Pan Hu. (2017) Clinical targeting recombinant immunotoxins for cancer therapy. OncoTargets and Therapy 10, pages 3645-3665.
Read now
Anna Wolska-Washer, Pawel Robak, Piotr Smolewski & Tadeusz Robak. (2017) Emerging antibody-drug conjugates for treating lymphoid malignancies. Expert Opinion on Emerging Drugs 22:3, pages 259-273.
Read now
Niaz Muhammad, Qinwen Mao & Haibin Xia. (2017) CAR T-cells for cancer therapy. Biotechnology and Genetic Engineering Reviews 33:2, pages 190-226.
Read now
Wenwen Wang, Elena Foerner, Eike Buss, Anna Jauch, Volker Eckstein, Patrick Wuchter, Anthony D. Ho & Christoph Lutz. (2017) Hematopoietic stem cells can be separated from leukemic cells in a subgroup of adult acute lymphoblastic leukemia patients. Leukemia & Lymphoma 58:6, pages 1446-1454.
Read now
Linlin Jiang, Ming Yang, Xiaoyun Zhang, Shiqi Bao, Li Ma, Dongmei Fan, Yuan Zhou, Dongsheng Xiong & Yongsu Zhen. (2016) A novel antibody–drug conjugate anti-CD19(Fab)-LDM in the treatment of B-cell non-Hodgkin lymphoma xenografts with enhanced anticancer activity. Journal of Drug Targeting 24:1, pages 47-57.
Read now
Jose A. Figueroa, Adair Reidy, Leonardo Mirandola, Kayley Trotter, Natallia Suvorava, Alejandro Figueroa, Venu Konala, Amardeep Aulakh, Lauren Littlefield, Fabio Grizzi, Rakhshanda Layeequr Rahman, Marjorie R. Jenkins, Breeanna Musgrove, Saba Radhi, Nicholas D'Cunha, Luke N. D'Cunha, Paul L. Hermonat, Everardo Cobos & Maurizio Chiriva-Internati. (2015) Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy. International Reviews of Immunology 34:2, pages 154-187.
Read now
Shira Dinner, Daniel Lee & Michaela Liedtke. (2014) Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leukemia & Lymphoma 55:8, pages 1715-1724.
Read now
Michael S Mathisen, Hagop M Kantarjian & Elias J Jabbour. (2014) Emerging drugs for acute lymphocytic leukemia. Expert Opinion on Emerging Drugs 19:1, pages 37-50.
Read now
Michael S. Mathisen, Hagop Kantarjian, Deborah Thomas, Susan O’Brien & Elias Jabbour. (2013) Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leukemia & Lymphoma 54:12, pages 2592-2600.
Read now
Ali Raufi, Abdul Shukkur Ebrahim & Ayad Al-Katib. (2013) Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Management and Research 5, pages 225-233.
Read now
L. Herrera, C. Stanciu-Herrera, C. Morgan, V. Ghetie & E. S. Vitetta. (2006) Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia. Leukemia & Lymphoma 47:11, pages 2380-2387.
Read now
Chizuru Kawano-Yamamoto, Kazuo Muroi, Thoru Izumi, Ken Saito & Keiya Ozawa. (2002) Two-color Flow Cytometry with a CD19 Gate for the Evaluation of Bone Marrow Involvement of B-cell Lymphoma. Leukemia & Lymphoma 43:11, pages 2133-2137.
Read now

Articles from other publishers (216)

Yunmeng Wang & Ping Cheng. (2024) Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1870:2, pages 166962.
Crossref
Jéssica A. Barbosa, Christine T. Yang, Arthur N. Finatto, Vinícius S. Cantarelli & Matheus de Oliveira Costa. (2023) T-independent B-cell effect of agents associated with swine grower-finisher diarrhea. Veterinary Research Communications.
Crossref
Wen-Da Wang, Yan-Yu Guo, Zhong-Lu Yang, Guang-Liang Su & Zhi-Jun Sun. (2023) Sniping Cancer Stem Cells with Nanomaterials. ACS Nano.
Crossref
Daniele Campolungo, Mara Salomé, Beatrice Biferali, Anna Sofia Tascini & Davide Gabellini. (2023) DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia. Science Advances 9:37.
Crossref
Mathew R. Schnorenberg, Katrina M. Hawley, Anika T. Thomas-Toth, Elyse A. Watkins, Yu Tian, Jeffrey M. Ting, Logan B. Leak, Isadora M. Kucera, Michal M. Raczy, Andrew L. Kung, Jeffrey A. Hubbell, Matthew V. Tirrell & James L. LaBelle. (2023) Targeted Polymersome Delivery of a Stapled Peptide for Drugging the Tumor Protein p53:BCL-2-Family Axis in Diffuse Large B-Cell Lymphoma. ACS Nano.
Crossref
Ryo Nishiyama, Kei Furuya, Phillip McCann, Laura Kacenauskaite, Bo W. Laursen, Amar H. Flood, Kotaro Hiramatsu & Keisuke Goda. (2023) Boosting the Brightness of Raman Tags Using Cyanostar Macrocycles. Analytical Chemistry 95:34, pages 12835-12841.
Crossref
Jinxia Ma, Lipei Shao, Tatyana Fuksenko, Hui Liu, Rongye Shi, Anh Dinh, Steven L. Highfill, Nan Zhang, Sandhya R. Panch, Robert P. Somerville, David F. Stroncek & Ping Jin. (2023) Reference gene selection for clinical chimeric antigen receptor T-cell product vector copy number assays. Cytotherapy 25:6, pages 598-604.
Crossref
Puja Bhattacharyya, Richard I. Christopherson, Kristen K. Skarratt, Jake Z. Chen, Thomas Balle & Stephen J. Fuller. (2023) Combination of High-Resolution Structures for the B Cell Receptor and Co-Receptors Provides an Understanding of Their Interactions with Therapeutic Antibodies. Cancers 15:11, pages 2881.
Crossref
Anil Kumar Mavi, Sonal Gaur, Gauri Gaur, Babita, Pragya Jindal, Neelesh Kumar & Umesh Kumar. (2023) CAR T-cell therapy: Reprogramming patient's immune cell to treat cancer. Cellular Signalling 105, pages 110638.
Crossref
Qi Gao, Xueyan Chen, Sindhu Cherian & Mikhail Roshal. (2022) Mature B‐ and plasma‐cell flow cytometric analysis: A review of the impact of targeted therapy. Cytometry Part B: Clinical Cytometry 104:3, pages 224-242.
Crossref
María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro & Roxana Schillaci. (2023) Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers 15:7, pages 1987.
Crossref
Benjamina Esapa, Jiexuan Jiang, Anthony Cheung, Alicia Chenoweth, David E. Thurston & Sophia N. Karagiannis. (2023) Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers 15:6, pages 1845.
Crossref
Huan Peng, Yunqing Lin, Fangxiao Hu, Cui Lv, Bingyan Wu, Qitong Weng, Lijuan Liu, Chengxiang Xia, Xiaofei Liu, Yalan Zhao, Qi Zhang, Yang Geng, Mengyun Zhang & Jinyong Wang. (2023) Prolonged generation of multi-lineage blood cells in wild-type animals from pluripotent stem cells. Stem Cell Reports 18:3, pages 720-735.
Crossref
Jiasen He, Faryal Munir, Dristhi Ragoonanan, Wafik Zaky, Sajad J Khazal, Priti Tewari, Juan Fueyo, Candelaria Gomez-Manzano & Hong Jiang. (2023) Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option. Immuno 3:1, pages 37-56.
Crossref
Surya K. De. 2023. Medicines for Cancer. Medicines for Cancer 489 540 .
Yaping Sun & Jian Xu. (2022) Emerging Antibodies in Cancer Therapy. Advanced NanoBiomed Research 3:1.
Crossref
Rebekah L Velounias & Thomas J Tull. (2022) Human B-cell subset identification and changes in inflammatory diseases. Clinical and Experimental Immunology 210:3, pages 201-216.
Crossref
Marilia Barreca, Noémie Lang, Chiara Tarantelli, Filippo Spriano, Paola Barraja & Francesco Bertoni. (2022) Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. Exploration of Targeted Anti-tumor Therapy, pages 763-794.
Crossref
Chiara Cassioli, Laura Patrussi, Salvatore Valitutti & Cosima T. Baldari. (2022) Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs). International Journal of Molecular Sciences 23:22, pages 14255.
Crossref
Chunrun Qu, Hao Zhang, Hui Cao, Lanhua Tang, Haoyang Mo, Fangkun Liu, Liyang Zhang, Zhenjie Yi, Lifu Long, Luzhe Yan, Zeyu Wang, Nan Zhang, Peng Luo, Jian Zhang, Zaoqu Liu, Weijie Ye, Zhixiong Liu & Quan Cheng. (2022) Tumor buster - where will the CAR-T cell therapy ‘missile’ go?. Molecular Cancer 21:1.
Crossref
Kyung-Han Lee, Kyung-Ho Jung & Jin Hee Lee. (2022) Immuno-PET Imaging and Radioimmunotherapy of Lymphomas. Molecular Pharmaceutics 19:10, pages 3484-3491.
Crossref
Hazim S. Ababneh, Jeremy S. Abramson, P. Connor Johnson & Chirayu G. Patel. (2022) Assessing the role of radiotherapy in patients with refractory or relapsed high-grade B-cell lymphomas treated with CAR T-cell therapy. Radiotherapy and Oncology 175, pages 65-72.
Crossref
Flavia Linguanti, Elisabetta Maria Abenavoli, Valentina Berti & Egesta Lopci. (2022) Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy. Cancers 14:19, pages 4700.
Crossref
Wei Yu, Hang Zhang, Yuncang Yuan, Jie Tang, Xinchuan Chen, Ting Liu & Xudong Zhao. (2022) Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia. Frontiers in Cell and Developmental Biology 10.
Crossref
Nicole B. Williams, Sana Batool, Hasan E. Zumrut, Rutika Patel, German Sosa, Mohammad Jamal & Prabodhika Mallikaratchy. (2022) An In Vitro Selection Platform to Identify Multiple Aptamers against Multiple Cell-Surface Markers Using Ligand-Guided Selection . Biochemistry 61:15, pages 1600-1613.
Crossref
Pinzheng Huang, Linfeng Xu, Mingming Jin, Lixi Li, Yizhong Ke, Min Zhang, Kairui Zhang, Kongyao Lu & Gang Huang. (2022) Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. Genes 13:6, pages 951.
Crossref
Zeljko Todorovic, Dusan Todorovic, Vladimir Markovic, Nevena Ladjevac, Natasa Zdravkovic, Predrag Djurdjevic, Nebojsa Arsenijevic, Marija Milovanovic, Aleksandar Arsenijevic & Jelena Milovanovic. (2022) CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings. Current Oncology 29:5, pages 3647-3657.
Crossref
Eliza Turlej, Tomasz Marek Goszczyński, Marek Drab, Beata Orzechowska, Magdalena Maciejewska, Joanna Banach & Joanna Wietrzyk. (2022) The Impact of Exosomes/Microvesicles Derived from Myeloid Dendritic Cells Cultured in the Presence of Calcitriol and Tacalcitol on Acute B-Cell Precursor Cell Lines with MLL Fusion Gene. Journal of Clinical Medicine 11:8, pages 2224.
Crossref
Firoza Mamdani, Matthieu D. Weber, Blynn Bunney, Kathleen Burke, Preston Cartagena, David Walsh, Francis S. Lee, Jack Barchas, Alan F. Schatzberg, Richard M. Myers, Stanley J. Watson, Huda Akil, Marquis P. Vawter, William E. Bunney & Adolfo Sequeira. (2022) Identification of potential blood biomarkers associated with suicide in major depressive disorder. Translational Psychiatry 12:1.
Crossref
Nawid Albinger, Rita Pfeifer, Marcus Nitsche, Sarah Mertlitz, Julia Campe, Katja Stein, Hermann Kreyenberg, Ralf Schubert, Melissa Quadflieg, Dina Schneider, Michael W. M. Kühn, Olaf Penack, Congcong Zhang, Nina Möker & Evelyn Ullrich. (2022) Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia. Blood Cancer Journal 12:4.
Crossref
Michael Boettcher, Alexander Joechner, Ziduo Li, Sile Fiona Yang & Patrick Schlegel. (2022) Development of CAR T Cell Therapy in Children—A Comprehensive Overview. Journal of Clinical Medicine 11:8, pages 2158.
Crossref
John A. ThompsonBryan J. SchneiderJulie BrahmerAmaka AchufusiPhilippe ArmandMeghan K. BerkenstockShailender BhatiaLihua E. BuddeSaurin ChokshiMarianne DaviesAmro ElshouryYaron GesthalterAparna HegdeMichael JainBenjamin H. KaffenbergerMelissa G. LechnerTianhong LiAlissa MarrSuzanne McGettiganJordan McPhersonTheresa MedinaNisha A. MohindraAnthony J. OlszanskiOlalekan OluwoleSandip P. PatelPradnya PatilSunil ReddyMabel RyderBianca SantomassoScott ShoferJeffrey A. SosmanYinghong WangVlad G. Zaha, Megan Lyons, Mary Dwyer & Lisa Hang. (2022) Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 20:4, pages 387-405.
Crossref
Tingting Zhang, Tian Wang, Fengtao You, Zixuan Li, Dan Chen, Kailu Zhang, Shuaiyu Tian, Binjie Sheng, Hai Wu, Licui Jiang, Renyuxue Ma, Gangli An, Huimin Meng & Lin Yang. (2022) Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. Transplant Immunology 71, pages 101538.
Crossref
Eyal Lebel, Boaz Nachmias, Marjorie Pick, Noa Gross Even-Zohar & Moshe E. Gatt. (2022) Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma. Journal of Clinical Medicine 11:7, pages 1809.
Crossref
Adalgisa Condoluci & Davide Rossi. (2022) Biology and Treatment of Richter Transformation. Frontiers in Oncology 12.
Crossref
Francesca Perutelli, Rebecca Jones, Valentina Griggio, Candida Vitale & Marta Coscia. (2022) Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges. Frontiers in Oncology 12.
Crossref
Somsak Prasongtanakij, Usanarat Anurathapan, Thitinee Vanichapol, Bunyada Jittorntrum, Korakot Atjanasuppat, Pongpak Pongpitcha, Samart Pakakasama, Duantida Songdej, Nongnuch Sirachainan, Karan Paisooksantivatana, Suparerk Borwaornpinyo, Borje S. Andersson & Suradej Hongeng. (2020) Production and characterization of haploidentical CD19 CAR T cells: Validated to induce a continuous complete remission in a patient with relapsed refractory B‐cell ALL. Asia-Pacific Journal of Clinical Oncology 18:1, pages 44-51.
Crossref
Samanta Romina Zanetti, Talia Velasco-Hernandez, Francisco Gutierrez-Agüera, Víctor M. Díaz, Paola Alejandra Romecín, Heleia Roca-Ho, Diego Sánchez-Martínez, Néstor Tirado, Matteo Libero Baroni, Paolo Petazzi, Raúl Torres-Ruiz, Oscar Molina, Alex Bataller, José Luis Fuster, Paola Ballerini, Manel Juan, Irmela Jeremias, Clara Bueno & Pablo Menéndez. (2022) A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy 30:2, pages 550-563.
Crossref
Omran Saifi, William G. Breen, Scott C. Lester, William G. Rule, Bradley Stish, Allison Rosenthal, Javier Munoz, Steven M. Herchko, Hemant S. Murthy, Yi Lin, Radhika Bansal, Matthew A. Hathcock, N. Nora Bennani, Jonas Paludo, Yucai Wang, Arushi Khurana, Jose C. Villasboas Bisneto, Patrick B. Johnston, Stephen M. Ansell, Madiha Iqbal, Han Tun, Ernesto Ayala, Mohamed A. Kharfan-Dabaja, Bradford S. Hoppe & Jennifer L. Peterson. (2022) Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiotherapy and Oncology 166, pages 171-179.
Crossref
Mohamed A. Kharfan-Dabaja, Farah Yassine, Martha E. Gadd & Hong Qin. (2022) Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. Transplantation and Cellular Therapy 28:1, pages 5-17.
Crossref
Manqiqige Su, Chongbo Zhao & Sushan Luo. (2022) Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. Autoimmunity Reviews 21:1, pages 102931.
Crossref
Alexander R. Coltoff & Joseph G. Jurcic. 2022. Nuclear Medicine and Molecular Imaging. Nuclear Medicine and Molecular Imaging 220 232 .
Anagha Deshpande, William Rule & Allison Rosenthal. (2022) Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. Current Treatment Options in Oncology 23:1, pages 89-98.
Crossref
Diana C. DeLucia & John K. Lee. 2022. Cancer Immunotherapies. Cancer Immunotherapies 1 48 .
Kieran D. Sahasrabudhe, Audrey M. Sigmund & Bhavana Bhatnagar. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 41 .
Michael Maschan, Paolo F. Caimi, Jane Reese-Koc, Gabriela Pacheco Sanchez, Ashish A. Sharma, Olga Molostova, Larisa Shelikhova, Dmitriy Pershin, Alexey Stepanov, Yakov Muzalevskii, Vinicius G. Suzart, Folashade Otegbeye, David Wald, Ying Xiong, Darong Wu, Adam Knight, Ibe Oparaocha, Beatrix Ferencz, Andre Roy, Andrew Worden, Winfried Kruger, Michael Kadan, Dina Schneider, Rimas Orentas, Rafick-Pierre Sekaly, Marcos de Lima & Boro Dropulić. (2021) Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nature Communications 12:1.
Crossref
Qi Zhang, Bingyan Wu, Qitong Weng, Fangxiao Hu, Yunqing Lin, Chengxiang Xia, Huan Peng, Yao Wang, Xiaofei Liu, Lijuan Liu, Jiapin Xiong, Yang Geng, Yalan Zhao, Mengyun Zhang, Juan Du & Jinyong Wang. (2021) Regeneration of immunocompetent B lymphopoiesis from pluripotent stem cells guided by transcription factors. Cellular & Molecular Immunology 19:4, pages 492-503.
Crossref
Anna Nydegger, Urban Novak, Marie-Noëlle Kronig, Myriam Legros, Sacha Zeerleder, Yara Banz, Ulrike Bacher & Thomas Pabst. (2021) Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients. Cancers 13:23, pages 6073.
Crossref
Shuhang Wang, Kun Chen, Qi Lei, Peiwen Ma, Andy Qingan Yuan, Yong Zhao, Youwei Jiang, Hong Fang, Shujun Xing, Yuan Fang, Ning Jiang, Huilei Miao, Minghui Zhang, Shujun Sun, Zicheng Yu, Wei Tao, Qi Zhu, Yingjie Nie & Ning Li. (2021) The state of the art of bispecific antibodies for treating human malignancies. EMBO Molecular Medicine 13:9.
Crossref
Nawid Albinger, Jessica Hartmann & Evelyn Ullrich. (2021) Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy 28:9, pages 513-527.
Crossref
Alejandrina Hernández-López, Mario A. Téllez-González, Paul Mondragón-Terán & Angélica Meneses-Acosta. (2021) Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Frontiers in Pharmacology 12.
Crossref
Nan Li, Madeline R. Spetz, Dan Li & Mitchell Ho. (2021) Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. Pharmacology & Therapeutics 223, pages 107892.
Crossref
Laura Cacciaguerra, Paola Tortorella, Maria A. Rocca & Massimo Filippi. (2021) Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. Neurotherapeutics 18:3, pages 1623-1636.
Crossref
Faroogh Marofi, Heshu Sulaiman Rahman, Muhammad Harun Achmad, Klunko Nataliya Sergeevna, Wanich Suksatan, Walid Kamal Abdelbasset, Maria Vladimirovna Mikhailova, Navid Shomali, Mahboubeh Yazdanifar, Ali Hassanzadeh, Majid Ahmadi, Roza Motavalli, Yashwant Pathak, Sepideh Izadi & Mostafa Jarahian. (2021) A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Frontiers in Immunology 12.
Crossref
Dorothee Winterberg, Lennart Lenk, Maren Oßwald, Fotini Vogiatzi, Carina Lynn Gehlert, Fabian-Simon Frielitz, Katja Klausz, Thies Rösner, Thomas Valerius, Anna Trauzold, Matthias Peipp, Christian Kellner & Denis Martin Schewe. (2021) Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo. Journal of Clinical Medicine 10:12, pages 2634.
Crossref
Veronika Mancikova & Michal Smida. (2021) Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences 22:11, pages 5536.
Crossref
Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. CaimiErin Reid, Owen A. O’ConnorJay M. FeingoldKirit M. ArdeshnaWilliam TownsendMelhem SolhLeonard T. HeffnerDavid UngarLuqiang WangJoseph BoniKarin Havenith, Yajuan QinBrad S. Kahl. (2021) Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 137:19, pages 2634-2645.
Crossref
Zachery Halford, Mary Kate Anderson, Lunawati L. Bennett & Jonathan Moody. (2020) Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations. Annals of Pharmacotherapy 55:4, pages 466-479.
Crossref
Shabirul Haque & Sarah R. Vaiselbuh. (2021) CD19 Chimeric Antigen Receptor-Exosome Targets CD19 Positive B-lineage Acute Lymphocytic Leukemia and Induces Cytotoxicity. Cancers 13:6, pages 1401.
Crossref
Natalie S. Grover, Nicholas Tschernia, Gianpietro Dotti & Barbara Savoldo. (2021) Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 + Tumors . Journal of Clinical Oncology 39:5, pages 499-513.
Crossref
Xiaonan Zhang & Tobias Sjöblom. (2021) Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy. Pharmaceuticals 14:1, pages 57.
Crossref
Krishna Goparaju, Allison Winter & Paolo F Caimi. (2021) The Anti-CD19 Antibody-Drug Conjugate Loncastuximab Tesirine. Oncology & Haematology 17:2, pages 95.
Crossref
Diego Alberto Bárcenas-López, Diana Karen Mendiola-Soto, Juan Carlos Núñez-Enríquez, Juan Manuel Mejía-Aranguré, Alfredo Hidalgo-Miranda & Silvia Jiménez-Morales. (2021) Promising genes and variants to reduce chemotherapy adverse effects in acute lymphoblastic leukemia. Translational Oncology 14:1, pages 100978.
Crossref
Nirav N. Shah, Adam Levin, Vivek S. Radhakrishnan & Parameswaran Hari. 2021. Contemporary Bone Marrow Transplantation. Contemporary Bone Marrow Transplantation 741 761 .
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Mohadese Hashem Boroojerdi, Fatemeh Rahbarizadeh, Pouya Safarzadeh Kozani, Elahe Kamali & Pooria Safarzadeh Kozani. (2020) Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Medical Oncology 37:11.
Crossref
Hilma J. van der Horst, Inger S. Nijhof, Tuna Mutis & Martine E. D. Chamuleau. (2020) Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies. Cancers 12:10, pages 3041.
Crossref
Andreas Viardot, Franco Locatelli, Julia Stieglmaier, Faraz Zaman & Elias Jabbour. (2020) Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Annals of Hematology 99:10, pages 2215-2229.
Crossref
Bicky ThapaPaolo F. CaimiKirit M. ArdeshnaMelhem SolhCarmelo Carlo-Stella, Brad S. Kahl & Mehdi Hamadani. (2020) CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Advances 4:16, pages 3850-3852.
Crossref
Zachery Halford, Mary Kate Anderson & Lunawati L. Bennett. (2020) Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Annals of Pharmacotherapy, pages 106002802094423.
Crossref
Kazushige Yoshida, Masanori Okamoto, Kaoru Aoki, Jun Takahashi & Naoto Saito. (2020) A Review of T-Cell Related Therapy for Osteosarcoma. International Journal of Molecular Sciences 21:14, pages 4877.
Crossref
Ajeet Gajra, Yolaine Jeune-Smith, Jonathan Kish, Ting-Chun Yeh, Skyler Hime & Bruce Feinberg. (2020) Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy 12:10, pages 725-732.
Crossref
Omran Saifi, Mohamed A. Kharfan-Dabaja, Youssef H. Zeidan, Jennifer Peterson, William G. Rule, Scott C. Lester & Bradford S. Hoppe. (2020) Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. International Journal of Particle Therapy 7:1, pages 13-20.
Crossref
Candida Vitale & Paolo Strati. (2020) CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. Frontiers in Oncology 10.
Crossref
Robert D. Carlson, John C. FlickingerJr.Jr. & Adam E. Snook. (2020) Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy. Toxins 12:4, pages 241.
Crossref
Shinji YamadaMika K. KanekoYusuke SayamaTeizo AsanoMasato SanoMiyuki YanakaTakuro NakamuraSaki OkamotoSaori HandaYu KomatsuYoshimi NakamuraYoshikazu FurusawaJunko TakeiYukinari Kato. (2020) Development of Novel Mouse Monoclonal Antibodies Against Human CD19. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 39:2, pages 45-50.
Crossref
Joseph G. Jurcic. (2020) Targeted Alpha-Particle Therapy for Hematologic Malignancies. Seminars in Nuclear Medicine 50:2, pages 152-161.
Crossref
Peter Braendstrup, Bruce L. Levine & Marco Ruella. (2020) The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy 22:2, pages 57-69.
Crossref
Talha Badar & Nirav N. Shah. (2020) Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Current Treatment Options in Oncology 21:2.
Crossref
Anuvrat Sircar, Sayan Chowdhury, Amber Hart, William Bell, Satishkumar Singh, Lalit Sehgal & Narendranath Epperla. (2020) Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. International Journal of Molecular Sciences 21:3, pages 904.
Crossref
Faizan Ahmad. (2020) Chimeric antigen receptor T-cell therapy in hematopoietic and nonhematopoietic malignancies. Biomedical and Biotechnology Research Journal (BBRJ) 4:3, pages 179.
Crossref
Peter A. Riedell & Michael R. Bishop. (2020) Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. Therapeutic Advances in Hematology 11, pages 204062072090289.
Crossref
R.J. Plenter, M.G. Coulombe, H.M. Roybal, C.M. Lin, R.G. Gill, M.R. Zamora & T.J. Grazia. (2020) C-kit-derived CD11b+ cells are critical for cardiac allograft prolongation by autologous C-kit+ progenitor cells. Cellular Immunology 347, pages 104023.
Crossref
Yu Zhong Peng, Li Jun Yang, Hang Hong Lo, Betty Yuen Kwan Law & Vincent Kam Wai Wong. 2020. New Nanomaterials and Techniques for Tumor-targeted Systems. New Nanomaterials and Techniques for Tumor-targeted Systems 135 229 .
Sajad Khazal & Kris Mahadeo. 2020. Oncologic Critical Care. Oncologic Critical Care 2035 2047 .
Nirav N. Shah, Adam Levin, Vivek Radhakrishnan & Parameswaran Hari. 2020. Contemporary Bone Marrow Transplantation. Contemporary Bone Marrow Transplantation 1 21 .
Renata Nacasaki Silvestre, Pablo Diego Moço & Virgínia Picanço-Castro. 2020. Chimeric Antigen Receptor T Cells. Chimeric Antigen Receptor T Cells 213 222 .
Bo Yu & Delong Liu. (2019) Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. Journal of Hematology & Oncology 12:1.
Crossref
Natalie S. Grover & Barbara Savoldo. (2019) Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer 19:1.
Crossref
Brad S. Kahl, Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo Caimi, Erin Reid, Jay M. Feingold, Kirit M. Ardeshna, Melhem Solh, Leonard T. Heffner, David Ungar, Shui He, Joseph Boni, Karin Havenith & Owen A. O'Connor. (2019) A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research 25:23, pages 6986-6994.
Crossref
Mohamad Mohty, Jordan Gautier, Florent Malard, Mahmoud Aljurf, Ali Bazarbachi, Christian Chabannon, Mohamed A. Kharfan-Dabaja, Bipin N. Savani, He Huang, Saad Kenderian, Arnon Nagler & Miguel-Angel Perales. (2019) CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. Leukemia 33:12, pages 2767-2778.
Crossref
Brian Hutzen, Siddhi Nath Paudel, Meisam Naeimi Kararoudi, Kevin A. Cassady, Dean A. Lee & Timothy P. Cripe. (2019) Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews 38:4, pages 573-594.
Crossref
Joshua A. HillElizabeth M. KrantzKevin A. Hay, Sayan DasguptaTerry Stevens-AyersRachel A. Bender Ignacio, Merav BarJoyce MaaloufSindhu Cherian, Xueyan Chen, Greg Pepper, Stanley R. RiddellDavid G. MaloneyMichael J. BoeckhCameron J. Turtle. (2019) Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. Blood Advances 3:22, pages 3590-3601.
Crossref
Yi-Feng Wu, Wei-Han Huang, Ming-Huei Gu, Siao-Ru Lin, Sung-Chao Chu, Tso-Fu Wang & Chi-Cheng Li. (2019) Higher CD56+ or CD2+ lymphocyte percentage predicts poor steroid response in patients with immune thrombocytopenia. Thrombosis Research 183, pages 63-68.
Crossref
Britten, Ragusa, Tosi & Kamel. (2019) MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?. Cells 8:11, pages 1341.
Crossref
Lu Hao, Tongtong Li, Lung-Ji Chang & Xiaochuan Chen. (2019) Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety. Current Medicinal Chemistry 26:17, pages 3068-3079.
Crossref
Luke Jones, Hannah McCalmont, Kathryn Evans, Chelsea Mayoh, Raushan T. Kurmasheva, Catherine A. Billups, Peter J. Houghton, Malcolm A. Smith & Richard B. Lock. (2019) Preclinical activity of the antibody‐drug conjugate denintuzumab mafodotin (SGN‐CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatric Blood & Cancer 66:8.
Crossref
Adam Levin & Nirav N. Shah. (2019) Chimeric antigen receptor modified T cell therapy in B cell non‐Hodgkin lymphomas. American Journal of Hematology 94:S1.
Crossref
Nirav N. Shah, Theresa Maatman, Parameswaran Hari & Bryon Johnson. (2019) Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Frontiers in Oncology 9.
Crossref
Julio C. Chavez, Christina Bachmeier & Mohamed A. Kharfan-Dabaja. (2019) CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Therapeutic Advances in Hematology 10, pages 204062071984158.
Crossref
Paola Kučan Brlić, Tihana Lenac Roviš, Guy Cinamon, Pini Tsukerman, Ofer Mandelboim & Stipan Jonjić. (2018) Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cellular & Molecular Immunology 16:1, pages 40-52.
Crossref
Sajad Khazal & Kris Mahadeo. 2019. Oncologic Critical Care. Oncologic Critical Care 1 13 .
Yanyu Pang, Xiaoyang Hou, Chunsheng Yang, Yanqun Liu & Guan Jiang. (2018) Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. Molecular Cancer 17:1.
Crossref
Xiao Han, Yao Wang & Wei‐Dong Han. (2018) Chimeric antigen receptor modified T‐cells for cancer treatment. Chronic Diseases and Translational Medicine 4:4, pages 225-243.
Crossref
Robert Havard & Deborah M. Stephens. (2018) Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma. Current Hematologic Malignancy Reports 13:6, pages 534-542.
Crossref
Kathryn L Black, Ammar S Naqvi, Mukta Asnani, Katharina E Hayer, Scarlett Y Yang, Elisabeth Gillespie, Asen Bagashev, Vinodh Pillai, Sarah K Tasian, Matthew R Gazzara, Martin Carroll, Deanne Taylor, Kristen W Lynch, Yoseph Barash & Andrei Thomas-Tikhonenko. (2018) Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Research.
Crossref
Jun Zhang, L. Jeffrey Medeiros & Ken H. Young. (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology 8.
Crossref
Kathleen W. Phelan & Anjali S. Advani. (2018) Novel Therapies in Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 13:4, pages 289-299.
Crossref
Julio C. Chavez & Frederick L. Locke. (2018) CAR T cell therapy for B-cell lymphomas. Best Practice & Research Clinical Haematology 31:2, pages 135-146.
Crossref
Cédric Rossi, Marie-Lorraine Chrétien & René-Olivier Casasnovas. (2018) Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targeted Oncology 13:3, pages 287-308.
Crossref
Shiqi Li, Jiasi Zhang, Meiling Wang, Gang Fu, Yunyan Li, Li Pei, Zhouxing Xiong, Dabing Qin, Rui Zhang, Xiaobo Tian, Zhihao Wei, Run Chen, Xuejiao Chen, Jia Wan, Jun Chen, Xia Wei, Yanmin Xu, Pei Zhang, Ping Wang, Xi Peng, Sainan Yang, Junjie Shen, Zhi Yang, Jieping Chen & Cheng Qian. (2018) Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB. British Journal of Haematology 181:3, pages 360-371.
Crossref
S. Makita & K. Tobinai. (2018) Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma. Annals of Oncology 29:5, pages 1086-1089.
Crossref
Maria-Luisa Schubert, Jean-Marc Hoffmann, Peter Dreger, Carsten Müller-Tidow & Michael Schmitt. (2018) Chimeric antigen receptor transduced T cells: Tuning up for the next generation. International Journal of Cancer 142:9, pages 1738-1747.
Crossref
Francesca ZammarchiSimon Corbett, Lauren Adams, Peter C. Tyrer, Konstantinos Kiakos, Narinder Janghra, Teresa Marafioti, Charles E. BrittenCarin E. G. HavenithSimon ChiversFrancois D’Hooge, David G. Williams, Arnaud Tiberghien, Philip W. Howard, John A. Hartley & Patrick H. van Berkel. (2018) ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies. Blood 131:10, pages 1094-1105.
Crossref
Fenlu Zhu, Nirav Shah, Huiqing Xu, Dina Schneider, Rimas Orentas, Boro Dropulic, Parameswaran Hari & Carolyn A. Keever-Taylor. (2018) Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy 20:3, pages 394-406.
Crossref
Joerg Schmohl, Deborah Todhunter, Elizabeth Taras, Veronika Bachanova & Daniel Vallera. (2018) Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies. Toxins 10:1, pages 32.
Crossref
Adrienne E. Borrie & Saman Maleki Vareki. 2018. Biology of T Cells - Part A. Biology of T Cells - Part A 201 276 .
Ying Qu, Ting Niu, Zhigang Liu, Bingyang Chu, Lan Zhang & Zhiyong Qian. (2017) Recent Progress of Doxorubicin Nanomedicine in Hematologic Malignancies. Nanoscience and Nanotechnology Letters 9:12, pages 1861-1874.
Crossref
Zhenguang Wang, Yelei Guo & Weidong Han. (2017) Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein & Cell 8:12, pages 896-925.
Crossref
Maureen C. Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner, Brad Meyer, Changpu Yu, Heather A. Van Epps & Dennis Benjamin. (2017) Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies. Blood 130:18, pages 2018-2026.
Crossref
David Pesántez, Adela Rodriguez, Aina Oliver-Caldés, Pablo Mozas & Jordi Esteve. (2017) Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia. European Medical Journal, pages 121-127.
Crossref
Joseph McGuirk, Edmund K. Waller, Muna Qayed, Sunil Abhyankar, Solveig Ericson, Peter Holman, Christopher Keir & G. Douglas Myers. (2017) Building blocks for institutional preparation of CTL019 delivery. Cytotherapy.
Crossref
Kiran Ghodke, Asma Bibi, Nikhil Rabade, Nikhil Patkar, P. G. Subramanian, Pratibha Aamre Kadam, Y. Badrinath, Sitaram Ghogale, Sumeet Gujral & Prashant Tembhare. (2017) CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases. Cytometry Part B: Clinical Cytometry 92:4, pages 315-318.
Crossref
Holly McConville, Megan Harvey, Colleen Callahan, Laura Motley, Heather Difilippo & Claire White. (2017) CAR T-Cell Therapy Effects: Review of Procedures and Patient Education
. Clinical Journal of Oncology Nursing 21:3.
Crossref
Sabine Blum, Filipe Martins & Michael Lübbert. (2017) Immunotherapy in adult acute leukemia. Leukemia Research.
Crossref
Robert J. Orlowski, David L. Porter & Noelle V. Frey. (2017) The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. British Journal of Haematology 177:1, pages 13-26.
Crossref
Shannon L. Maude. (2017) Future directions in chimeric antigen receptor T cell therapy. Current Opinion in Pediatrics 29:1, pages 27-33.
Crossref
Sara Ghorashian & Persis Amrolia. 2017. Childhood Acute Lymphoblastic Leukemia. Childhood Acute Lymphoblastic Leukemia 239 254 .
Alessandro Allegra, Vanessa Innao, Demetrio Gerace, Doriana Vaddinelli & Caterina Musolino. (2016) Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. Blood Cells, Molecules, and Diseases 62, pages 49-63.
Crossref
Maria-Luisa SchubertAngela HückelhovenJean-Marc HoffmannAnita SchmittPatrick WuchterLeopold SellnerSusanne HofmannAnthony D. HoPeter DregerMichael Schmitt. (2016) Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation. Human Gene Therapy 27:10, pages 758-771.
Crossref
Deepa Jagadeesh & Mitchell R. Smith. (2016) Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma. Current Treatment Options in Oncology 17:10.
Crossref
Andrew D. Fesnak, Carl H. June & Bruce L. Levine. (2016) Engineered T cells: the promise and challenges of cancer immunotherapy. Nature Reviews Cancer 16:9, pages 566-581.
Crossref
Matthew J. Frigault & Marcela V. Maus. (2016) Chimeric antigen receptor-modified T cells strike back. International Immunology 28:7, pages 355-363.
Crossref
Aneel Paulus, Sikander Ailawadhi & Asher Chanan-Khan. (2016) Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Practice & Research Clinical Haematology 29:2, pages 216-228.
Crossref
Aharon Ronson, Ariella Tvito & Jacob M. Rowe. (2016) Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults. Current Oncology Reports 18:6.
Crossref
. 2016. Leong's Manual of Diagnostic Antibodies for Immunohistology. Leong's Manual of Diagnostic Antibodies for Immunohistology 79 80 .
Marcela V. Maus & Bruce L. Levine. (2016) Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. The Oncologist 21:5, pages 608-617.
Crossref
Marcela V. Maus & Carl H. June. (2016) Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clinical Cancer Research 22:8, pages 1875-1884.
Crossref
Tadeusz Robak, Jerzy Z. Blonski & Pawel Robak. (2016) Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia. Seminars in Oncology 43:2, pages 280-290.
Crossref
Na An, Zhongfei Tao, Saisai Li, Haiyan Xing, Kejing Tang, Zheng Tian, Qing Rao, Min Wang & Jianxiang Wang. (2016) Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells. Oncotarget 7:9, pages 10638-10649.
Crossref
Hakan Goker, Umit Yavuz Malkan, Haluk Demiroglu & Yahya Buyukasik. (2016) Chimeric antigen receptor T cell treatment in hematologic malignancies. Transfusion and Apheresis Science 54:1, pages 35-40.
Crossref
Carlos A. Ramos, Helen E. HeslopMalcolm K. Brenner. (2016) CAR-T Cell Therapy for Lymphoma. Annual Review of Medicine 67:1, pages 165-183.
Crossref
Andrew Walls, Sarah Dermody, Ravindran Kumaran, Nathan Krishnan & Earl H. Harley. (2016) Characterization of B-Cells in tonsils of patients diagnosed with pediatric autoimmune neuropsychiatric disorder associated streptococcus. International Journal of Pediatric Otorhinolaryngology 80, pages 49-52.
Crossref
Joshua Seth EatonPaul E. MillerMark J. MannisChristopher J. Murphy. (2015) Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials. Journal of Ocular Pharmacology and Therapeutics 31:10, pages 589-604.
Crossref
C. L. Lorentzen & P. T. Straten. (2015) CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia. Scandinavian Journal of Immunology 82:4, pages 307-319.
Crossref
Holly J. Meany, Nita L. Seibel, Mark Krailo, Doojduen Villaluna, Zhengjia Chen, Paul Gaynon, Joseph P. Neglia, Julie R. Park, Raymond Hutchinson, Judith K. Sato, Robert J. Wells, William G. Woods & Gregory Reaman. (2015) Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL. Journal of Immunotherapy 38:7, pages 299-305.
Crossref
Steven A. Feldman, Yasmine Assadipour, Isaac Kriley, Stephanie L. Goff & Steven A. Rosenberg. (2015) Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Seminars in Oncology 42:4, pages 626-639.
Crossref
Shannon L. MaudeDavid T. TeacheyDavid L. Porter & Stephan A. Grupp. (2015) CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125:26, pages 4017-4023.
Crossref
Elias Jabbour, Susan O’Brien, Farhad Ravandi & Hagop Kantarjian. (2015) Monoclonal antibodies in acute lymphoblastic leukemia. Blood 125:26, pages 4010-4016.
Crossref
Naresh Bumma, Nikolaos Papadantonakis & Anjali S Advani. (2015) Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. Future Oncology 11:12, pages 1729-1739.
Crossref
E. Erica Hong, Hans Erickson, Robert J. Lutz, Kathleen R. Whiteman, Gregory Jones, Yelena Kovtun, Veronique Blanc & John M. Lambert. (2015) Design of Coltuximab Ravtansine, a CD19-Targeting Antibody–Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure–Activity Relationships and Preclinical Evaluation. Molecular Pharmaceutics 12:6, pages 1703-1716.
Crossref
Veronika Bachanova, Arthur E. Frankel, Qing Cao, Dixie Lewis, Bartosz Grzywacz, Michael R. Verneris, Celalettin Ustun, Aleksandr Lazaryan, Brian McClune, Erica D. Warlick, Hagop Kantarjian, Daniel J. Weisdorf, Jeffrey S. Miller & Daniel A. Vallera. (2015) Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies. Clinical Cancer Research 21:6, pages 1267-1272.
Crossref
Xiaojun YuMarta IleckaEmmalene J. BartlettViktor SchneidtRauf BhatJosef Mautner, Regina FeederleHenri-Jacques Delecluse. (2015) Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells. Blood 125:10, pages 1601-1610.
Crossref
Brian C. Miller & Marcela V. Maus. (2015) CD19-Targeted CAR T Cells: A New Tool in the Fight against B Cell Malignancies. Oncology Research and Treatment 38:12, pages 683-690.
Crossref
Shannon L. Maude, Elizabeth J. Shpall & Stephan A. Grupp. (2014) Chimeric antigen receptor T-cell therapy for ALL. Hematology 2014:1, pages 559-564.
Crossref
Jennifer A. WoyachFarrukh AwanIan W. FlinnJesus G. BerdejaElizabeth WileySharmeen Mansoor, Ying HuangGerard Lozanski, Paul A. Foster & John C. Byrd. (2014) A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood 124:24, pages 3553-3560.
Crossref
Caroline S Breton, Aimable Nahimana, Dominique Aubry, Julie Macoin, Pierre Moretti, Martin Bertschinger, Samuel Hou, Michel A Duchosal & Jonathan Back. (2014) A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. Journal of Hematology & Oncology 7:1.
Crossref
Frank R. Brennan. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies 1115 1126 .
Jennifer R. BrownDavid L. PorterSusan M. O'Brien. (2014) Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward. American Society of Clinical Oncology Educational Book:34, pages e317-e325.
Crossref
Carlos A. Ramos, Barbara Savoldo & Gianpietro Dotti. (2014) CD19-CAR Trials. The Cancer Journal 20:2, pages 112-118.
Crossref
Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haioun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljajic, Anne Caron, Sandrine Payrard & Bertrand Coiffier. (2014) A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Cancer Research 20:1, pages 213-220.
Crossref
Barbara Tumaini, Daniel W. Lee, Tasha Lin, Luciano Castiello, David F. Stroncek, Crystal Mackall, Alan Wayne & Marianna Sabatino. (2013) Simplified process for the production of anti–CD19-CAR–engineered T cells. Cytotherapy 15:11, pages 1406-1415.
Crossref
Rohan MathurGeorge J. Weiner. (2013) Picking the Optimal Target for Antibody-Drug Conjugates. American Society of Clinical Oncology Educational Book:33, pages e103-e107.
Crossref
James N. Kochenderfer & Steven A. Rosenberg. (2013) Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature Reviews Clinical Oncology 10:5, pages 267-276.
Crossref
Filiz Demircik, Thorsten Buch & Ari Waisman. (2013) Efficient B Cell Depletion via Diphtheria Toxin in CD19-Cre/iDTR Mice. PLoS ONE 8:3, pages e60643.
Crossref
Partow KebriaeiFarhad Ravandi. (2013) Treating adults with acute lymphoblastic leukemia: it is time to grow up. International Journal of Hematologic Oncology 2:1, pages 5-8.
Crossref
Rodney A. Prell, Donna W. Lee, Wendy G. Halpern & Anu V. Connor. 2013. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics 343 371 .
John M. Lambert, Veronique Blanc, Nathalie Le Bail & Anne Bousseau. 2013. Antibody-Drug Conjugates and Immunotoxins. Antibody-Drug Conjugates and Immunotoxins 149 160 .
Lisa M. Pörtner, Kathrin Schönberg, Maryam Hejazi, Daniela Brünnert, Frank Neumann, Lars Galonska, Uwe Reusch, Melvyn Little, Rainer Haas & Markus Uhrberg. (2012) T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16. Cancer Immunology, Immunotherapy 61:10, pages 1869-1875.
Crossref
Jonathan C. Poe, Veronique Minard-Colin, Evgueni I. Kountikov, Karen M. Haas & Thomas F. Tedder. (2012) A c-Myc and Surface CD19 Signaling Amplification Loop Promotes B Cell Lymphoma Development and Progression in Mice. The Journal of Immunology 189:5, pages 2318-2325.
Crossref
Elaine Y. Chung, James N. Psathas, Duonan Yu, Yimei Li, Mitchell J. Weiss & Andrei Thomas-Tikhonenko. (2012) CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis. Journal of Clinical Investigation 122:6, pages 2257-2266.
Crossref
Craig A. Portell & Anjali S. Advani. (2012) Antibody Therapy for Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports 7:2, pages 153-159.
Crossref
Kevin J. Curran, Hollie J. Pegram & Renier J. Brentjens. (2012) Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. The Journal of Gene Medicine 14:6, pages 405-415.
Crossref
Henrik E Mei, Stefanie Schmidt & Thomas Dörner. (2012) Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Research & Therapy 14:Suppl 5, pages S1.
Crossref
Renier J. BrentjensIsabelle RivièreJae H. ParkMarco L. DavilaXiuyan WangJolanta StefanskiClare TaylorRaymond YehShirley BartidoOriana Borquez-OjedaMalgorzata OlszewskaYvette BernalHollie PegramMark PrzybylowskiDaniel HollymanYelena UsachenkoDomenick PirragliaJames HoseyElmer Santos, Elizabeth HaltonPeter MaslakDavid ScheinbergJoseph JurcicMark HeaneyGlenn Heller, Mark FrattiniMichel Sadelain. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118:18, pages 4817-4828.
Crossref
Elizabeth Ward, Nanette Mittereder, Ellen Kuta, Gary P. Sims, Michael A. Bowen, William Dall’Acqua, Thomas Tedder, Peter Kiener, Anthony J. Coyle, Herren Wu, Bahija Jallal & Ronald Herbst. (2011) A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. British Journal of Haematology 155:4, pages 426-437.
Crossref
Veronique Blanc, Anne Bousseau, Anne Caron, Chantal Carrez, Robert J. Lutz & John M. Lambert. (2011) SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies. Clinical Cancer Research 17:20, pages 6448-6458.
Crossref
Xiao‐Yun Liu, Laurentiu M. Pop, Lydia Tsai, Iliodora V. Pop & Ellen S. Vitetta. (2010) Chimeric, divalent and tetravalent anti‐CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B‐cell lymphoma and pre‐B acute lymphoblastic leukemia cell lines . International Journal of Cancer 129:2, pages 497-506.
Crossref

Displaying 200 of 238 citing articles. Use the download link below to view the full list of citing articles.

Download full citations list

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.